Abstract Library

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,

#4315 The indolent nature of type 1 gastric neuroendocrine tumours under 1cm: Insights from a dual-centre study

Introduction: Current guidelines primarily recommend endoscopic surveillance for type 1 gastric neuroendocrine tumours (g-NETs) measuring ≤10mm, though these guidelines are largely based on expert consensus rather than strong evidence.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Rinzivillo M, Esposito G,

Keywords: Gastric Neuroendocrine Tumour, Carcinoid, Endoscopic Surveillance,